The Effect of Dexamethasone on IL-6 Levels in Confirmed COVID-19 Patients Treated at RSUP Dr. M. Djamil Padang

Bobby Hasibuan, Irvan Medison, Fenty Anggrainy

Abstract


Background: Elevated IL-6 levels have been found in COVID-19 patients and are associated with a poor prognosis. According to COVID-19 management guidelines, several types of corticosteroids can be used as therapy modalities for COVID-19 patients, including dexamethasone, methylprednisolone, and hydrocortisone. The purpose of this study was to examine how dexamethasone administration affected changes in IL-6 levels in confirmed COVID-19 patients at RSUP Dr. M. Djamil Padang.

Methods: This was a retrospective cohort study with a sample of all COVID-19 patients who met the inclusion and exclusion criteria and were treated in the COVID-19 isolation ward at RSUP Dr. M. Djamil Padang. The study began in June 2021 and concluded in July 2022. The data was analyzed both descriptively and analytically. The distribution of frequencies and proportions of each variable was included in the univariate analysis. Bivariate analysis employs data-scale-appropriate statistical tests such as the T-test to determine the relationship between independent and dependent variables.

Results: The characteristic of the patients were mostly 18-49 years old (37.22%), female (55.67%), of severe clinical degree (49.44%), had no comorbidities (52.78%) and the majority (77.78%) received dexamethasone in the recommended dose (1 x 6 mg). The study's findings revealed that there was no difference in IL-6 values before and after dexamethasone administration in patients with moderate clinical degrees,  but there were differences in IL-6 values before and after dexamethasone administration in patients with severe and critical clinical degrees.

Conclusion: The IL-6 level has significantly decreased following dexamethasone administration. Dexamethasone administration causes significant changes in IL-6 values in severe and critical degrees but not in moderate clinical degree.


Keywords


COVID-19; Dexamethasone; IL-6

Full Text:

PDF

References


Ikatan Dokter Indonesia. COVID-19. Ikatan Dokter Indonesia. 2020.

Gallelli L, Zhang L, Wang T, Fu F. Severe acute lung injury related to COVID-19 infection: A review and the possible role for escin. J Clin Pharmacol. 2020;60(7):815–25.

Magro G. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the “culprit lesion” of ARDS onset? What is there besides Tocilizumab? SGP130Fc. Cytokine X. 2020;2(2):100029.

Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). medRxiv. 2020;2020.02.18.20024364.

Gubernatorova EO, Gorshkova EA, Polinova AI, Drutskaya MS. IL-6: relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020;53:13–24.

Ali MJ, Hanif M, Haider MA, Ahmed MU, Sundas FNU, Hirani A, et al. Treatment options for COVID-19: A review. Front Med (Lausanne). 2020;7:558346.

Caramori G, Mumby S, Girbino G, Chung KF, Adcock IM. Corticosteroids. Nijkamp and Parnham’s Principles of Immunopharmacology. 2019;661–88.

Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.

PDPI, PERKI, PAPDI, PERDATIN, IDAI. Pedoman tatalaksana COVID-19: Edisi 4. Indonesia: 4; 2022.

Awasthi S, Wagner T, Venkatakrishnan AJ, Puranik A, Hurchik M, Agarwal V, et al. Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients. Cell Death Discov. 2021;7(1):55.

Santa Cruz A, Mendes-Frias A, Oliveira AI, Dias L, Matos AR, Carvalho A, et al. Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia. Front Immunol. 2021;12:613422.

Gorham J, Moreau A, Corazza F, Peluso L, Ponthieux F, Talamonti M, et al. Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis. PLoS One. 2020;15(12):e0244628.

Al-Mudhaffer RH, Ahjel SW, Hassan SM, Mahmood AA, Hadi NR. Age distribution of clinical symptoms, isolation, co-morbidities and case fatality rate of COVID-19 cases in Najaf City, Iraq. Medical Archives. 2020;74(5):363–7.

Tabernero E, Ruiz LA, España PP, Méndez R, Serrano L, Santos B, et al. COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences. Infection. 2022;50(1):179–89.

Gómez-Belda AB, Fernández-Garcés M, Mateo-Sanchis E, Madrazo M, Carmona M, Piles-Roger L, et al. COVID-19 in older adults: What are the differences with younger patients? Geriatr Gerontol Int. 2021;21(1):60–5.

Perrotta F, Corbi G, Mazzeo G, Boccia M, Aronne L, D’Agnano V, et al. COVID-19 and the elderly: Insights into pathogenesis and clinical decision-making. Aging Clin Exp Res. 2020;32(8):1599–608.

Liu Y, Mao B, Liang S, Yang JW, Lu HW, Chai YH, et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur Respir J. 2020;55(5):2001112.

Surendra H, Elyazar IR, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. Lancet Reg Health West Pac. 2021;9:100108.

Fortunato F, Martinelli D, Lo Caputo S, Santantonio T, Dattoli V, Lopalco PL, et al. Sex and gender differences in COVID-19: an Italian local register-based study. BMJ Open. 2021;11(10):e051506.

Fernández-De-las-peñas C, Martín-Guerrero JD, Pellicer-Valero ÓJ, Navarro-Pardo E, Gómez-Mayordomo V, Cuadrado ML, et al. Female sex is a risk factor associated withlong-term post-COVID related-symptoms but not with COVID-19 symptoms: The LONG-COVID-EXP-CM multicenter study. J Clin Med. 2022;11(2):413.

Doerre A, Doblhammer G. The influence of gender on COVID-19 infections and mortality in Germany: Insights from age- and gender-specific modeling of contact rates, infections, and deaths in the early phase of the pandemic. PLoS One. 2022;17(5):e0268119.

Raimondi F, Novelli L, Ghirardi A, Russo FM, Pellegrini D, Biza R, et al. Covid-19 and gender: Lower rate but same mortality of severe disease in women-an observational study. BMC Pulm Med. 2021;21(1):96.

Gagliardi MC, Tieri P, Ortona E, Ruggieri A. ACE2 expression and sex disparity in COVID-19. Cell Death Discov. 2020;6(1):37.

Kidron R, Robinson S. The importance of computerized tomography in psychiatry. Israel Journal of Psychiatry and Related Sciences. 1982;19(2):165–72.

Liu F, Ji C, Luo J, Wu W, Zhang J, Zhong Z, et al. Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019. Scientific Reports 2020 10:1. 2020;10(1):1–9.

Gong J, Dong H, Xia QS, Huang Z yi, Wang D kun, Zhao Y, et al. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: A retrospective study. BMC Infect Dis. 2020;20(1):963.

Su JH, Luo MY, Liang N, Gong SX, Chen W, Huang WQ, et al. Interleukin-6: A novel target for cardio-cerebrovascular diseases. Front Pharmacol. 2021;12:745061.

Bordallo B, Bellas M, Cortez AF, Vieira M, Pinheiro M. Severe COVID-19: What have we learned with the immunopathogenesis? Adv Rheumatol. 2020;60(1):50.

Dequin PF, Heming N, Meziani F, Plantefève G, Voiriot G, Badié J, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: A randomized clinical trial. JAMA. 2020;324(13):1298–306.

Granholm A, Kjær MBN, Munch MW, Myatra SN, Vijayaraghavan BKT, Cronhjort M, et al. Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia. Intensive Care Med. 2022;48(5):580–9.

FakhriRavari A, Jin S, Kachouei FH, Le D, Lopez M. Systemic corticosteroids for management of COVID-19: Saving lives or causing harm? Int J Immunopathol Pharmacol. 2021;35:20587384211063976.

Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38–42.

Yudistira R, Ananda D, Kurniati N, Hudari H, Bahar E. Correlation of interleukin-6 levels with clinical features and chest x-ray imaging in coronavirus disease-19 (COVID-19) patients at Dr. Mohammad Hoesin General Hospital Palembang. Bioscientia Medicina : Journal of Biomedicine and Translational Research. 2022;6(5):1799–805.

Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: A highly regulated and dynamic system. Cytokine. 2014;70(1):11–20.

Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123–30.

Mojtabavi H, Saghazadeh A, Rezaei N. Interleukin-6 and severe COVID-19: A systematic review and meta-analysis. Eur Cytokine Netw. 2020;31(2):44–9.

Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146(1):128-136.e4.

Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ. 2020;368:m1091.

Xiang Z, Liu J, Shi D, Chen W, Li J, Yan R, et al. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. Int J Biol Sci. 2020;16(13):2382–91.

Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636–43.

Xiong B, Du H, Zhan Z, Zhang A, He LM, Qin YY, et al. Effectiveness of adjunctive corticosteroid therapy in patients with severe COVID-19: A retrospective cohort study. World J Clin Cases. 2021;9(15):3546–58.

Fujino M, Ishii M, Taniguchi T, Chiba H, Kimata M, Hitosugi M. The value of interleukin-6 among several inflammatory markers as a predictor of respiratory failure in COVID-19 patients. Diagnostics (Basel). 2021;11(8):1327.

King EM, Chivers JE, Rider CF, Minnich A, Giembycz MA, Newton R. Glucocorticoid repression of inflammatory gene expression shows differential responsiveness by transactivation- and transrepression-dependent mechanisms. PLoS One. 2013;8(1):e53936.

Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: A systematic review and meta-analysis. Rev Med Virol. 2020;30(6):1–9.

Wang J, Yang W, Chen P, Guo J, Liu R, Wen P, et al. The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis. PLoS One. 2021;16(4):e0249481.

Chen H, Xie J, Su N, Wang J, Sun Q, Li S, et al. Corticosteroid therapy is associated with improved outcome in critically ill patients with COVID-19 with hyperinflammatory phenotype. Chest. 2021;159(5):1793–802.

Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2(8):1069–76.

Barh D, Aljabali AA, Tambuwala MM, Tiwari S, Serrano-Aroca Á, Alzahrani KJ, et al. Predicting COVID-19-comorbidity pathway crosstalk-based targets and drugs: Towards personalized COVID-19 management. Biomedicines. 2021;9(5):556.

Zúñiga MÁL, Moreno-Moral A, Ocaña-Granados A, Padilla-Moreno FA, Castillo-Fernández AM, Guillamón-Fernández D, et al. High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response. PLoS One. 2021;16(1):e0243964.

The COVID STEROID 2 Trial Group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: The COVID STEROID 2 randomized trial. JAMA. 2021;326(18):1807–17.




DOI: https://doi.org/10.36497/jri.v43i3.426

Refbacks

  • There are currently no refbacks.




Copyright (c) 2023 Bobby Hasibuan, Irvan Medison, Fenty Anggrainy


INDEXING & PARTNER

SINTA Garuda Indonesian Scientific Journal Database (ISJD) Indonesia One Search (IOS) Crossref

ROAD-ISSN Dimensions Google Scholar 

 

Jurnal Respirologi Indonesia
pISSN: 0853-7704 - eISSN: 2620-3162
Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia
Phone: +62-21-2247-4845
Email: editor@jurnalrespirologi.org


An official publication by
the Indonesian Society of Respirology (ISR)

Creative Commons License
Creative Commons Attribution-ShareAlike 4.0 International License

Statcounter